Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 59%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is poised for growth with their successful Guardant360 and Reveal tests, as well as the launch of their new GH Shield blood test and expansion of their services. However, there may be challenges ahead with competition and bringing new tests to market, which may require careful management of costs. Investors should closely monitor the company's pipeline and strategic developments to assess future success.

Bears say

Guardant Health is a precision oncology company that offers genomic profiling and cancer screening tests. However, its reliance on its flagships product, Guardant360, poses a risk as volume deceleration may lead to a decrease in sales. The company also faces competition in the precision oncology diagnostics industry, which may impact its market share. Additionally, while the company has achieved some major milestones, its high valuation and volatility in the precision oncology space also pose risks to its outlook.

GH has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 59% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 22 analysts, GH has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $181.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $181.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.